Related references
Note: Only part of the references are listed.Lung Cancer in Nepal
Ramila Shilpakar et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020
Aakash Desai et al.
JAMA NETWORK OPEN (2022)
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
David Planchard et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis
Hendrik Ungefroren
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Unlocking the potential of antibody-drug conjugates for cancer therapy
Joshua Z. Drago et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
Sareshma Sudhesh Dev et al.
FRONTIERS IN PHARMACOLOGY (2021)
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial
Caicun Zhou et al.
JAMA ONCOLOGY (2021)
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
Yue Pan et al.
FRONTIERS IN ONCOLOGY (2021)
Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges
Xabier Mielgo-Rubio et al.
FUTURE ONCOLOGY (2021)
Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy
Masashi Mikubo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Cycling cancer persister cells arise from lineages with distinct programs
Yaara Oren et al.
NATURE (2021)
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Heidie Frisco Cabanos et al.
CANCERS (2021)
Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib
Yan Zhang et al.
PATHOLOGY & ONCOLOGY RESEARCH (2021)
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
J. Mazieres et al.
ANNALS OF ONCOLOGY (2020)
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
Julia Roeper et al.
Oncotarget (2020)
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Alvaro Quintanal-Villalonga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
S. S. Schalm et al.
ANNALS OF ONCOLOGY (2020)
Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews
Marina T. Van Leeuwen et al.
JNCI CANCER SPECTRUM (2020)
Non-genetic mechanisms of therapeutic resistance in cancer
Jean-Christophe Marine et al.
NATURE REVIEWS CANCER (2020)
Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
Kei Kunimasa et al.
JACC: CARDIOONCOLOGY (2020)
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
Chien-Hui Weng et al.
ONCOGENE (2019)
Age at diagnosis is a heterogeneous factor for non-small cell lung cancer patients
Tao Chen et al.
JOURNAL OF THORACIC DISEASE (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
460PA phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours
J Sarantopoulos et al.
ANNALS OF ONCOLOGY (2019)
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu et al.
MOLECULAR CANCER (2019)
EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
Xuan Zhu et al.
FRONTIERS IN ONCOLOGY (2019)
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
Isabelle Solassol et al.
BIOMOLECULES (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations
Christina Alidousty et al.
JOURNAL OF PATHOLOGY (2018)
EGFR-TKIs resistance via EGFR-independent signaling pathways
Qian Liu et al.
MOLECULAR CANCER (2018)
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
Chia-Yu Chu et al.
ONCOLOGIST (2018)
ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?
Charbel Hobeika et al.
PERSONALIZED MEDICINE (2018)
Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
Romain Corre et al.
Oncotarget (2018)
TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib
Wen-Xian Wang et al.
JOURNAL OF THORACIC DISEASE (2018)
Management of Brain Metastases in epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
William J. Kelly et al.
FRONTIERS IN ONCOLOGY (2018)
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
A. Kron et al.
ANNALS OF ONCOLOGY (2018)
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Juanita S. Lopez et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer
Surein Arulananda et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Targeting Lung Cancer Stem Cells: Research and Clinical Impacts
Norashikin Zakaria et al.
FRONTIERS IN ONCOLOGY (2017)
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Dana S. Neel et al.
NPJ PRECISION ONCOLOGY (2017)
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
Shuhang Wang et al.
CANCER LETTERS (2017)
Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib
N. Takegawa et al.
ANNALS OF ONCOLOGY (2016)
Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors
Annelieke E. C. A. B. Willemsen et al.
DRUG DISCOVERY TODAY (2016)
Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib
Shiro Fujita et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management
Khurum H. Khan et al.
ONCOLOGIST (2016)
The biological role of epithelial-mesenchymal transition in lung cancer (Review)
Woo Jung Sung et al.
ONCOLOGY REPORTS (2016)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Matthew J. Niederst et al.
NATURE COMMUNICATIONS (2015)
Assessment of the Drug Interaction Potential and Single- and Repeat-Dose Pharmacokinetics of the BRAF Inhibitor Dabrafenib
A. Benjamin Suttle et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions
Solange Peters et al.
CANCER TREATMENT REVIEWS (2014)
Evolving concepts of tumor heterogeneity
Victoria R. Zellmer et al.
CELL AND BIOSCIENCE (2014)
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China
Yi-Long Wu et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2012)
A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer
Andrew Weickhardt et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements
Andrew J. Holland et al.
NATURE MEDICINE (2012)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker
Emily S. Robinson et al.
SEMINARS IN NEPHROLOGY (2010)
Epidermal growth factor receptor double activating mutations involving both Exons 19 and 21 exist in chinese non-small cell lung cancer patients
G-C. Zhang et al.
CLINICAL ONCOLOGY (2007)
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers
Masaharu Nomura et al.
PLOS MEDICINE (2007)
Gene amplification in cancer
Donna G. Albertson
TRENDS IN GENETICS (2006)
FDA drug approval summary:: Erlotinib (Tarceva®) tablets
MH Cohen et al.
ONCOLOGIST (2005)
Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system
CY Wu et al.
PHARMACEUTICAL RESEARCH (2005)
Share Paper
